Ramciclane is a bicycloheptyloxyethanamine derivative that acts with sedative activity.

Razobazam (Hoe 175) is a benzodiazepine derivative. Benzodiazepines are mainly used for treatment of anxiety. Razobazam improves learning performance in socially deprived rats. A 13% increase in neuronal density in the frontal cortex (associated with complex cognitive functions) of rats treated with razobazam was observed, but no changes in the amygdala (involved in emotion and memory functions). In mice, razobazam also affects retention performance through influences on memory storage and retrieval.

Radequinil (also known as AC-3933 ) is a oxadiazolylnaphthyridinone derivative patented by Dainippon Pharmaceutical Co., Ltd. as an inverse agonist of benzodiazepine receptors useful for the treatment of cognitive disorders including Alzheimer's disease. In preclinical trials, Radequinil enhances acetylcholine release in the rat hippocampus and ameliorates scopolamine-induced memory impairment and age-related cognitive decline in both rats and mice. Unlike the acetylcholinesterase inhibitor donepezil and the benzodiazepine receptor inverse agonist FG-7142, oral administration of Radequinil significantly ameliorated MK-801-induced memory impairment in the Y-maze test and in the object location test. Interestingly, the procognitive effects of Radequinil on MK-801-induced memory impairment were not affected by the benzodiazepine receptor antagonist flumazenil, although this was not the case for the beneficial effects of Radequinil on scopolamine-induced memory deficit. Moreover, the onset of Radequinil ameliorating effect on scopolamine- or MK-801-induced memory impairment was different in the Y-maze test. Unfortunately, in clinical trials, Radequinil failed to demonstrate efficacy and further development was discontinued.

Renanolone is a synthetic neuroactive C21 5β-H steroid. It was never used in a clinical setting. The thermogenic and inflammatory responses induced by renanolone were reported to be similar to responses induced generally by appropriate administration of neutral steroid pyrogens in humans.

Tafluposide (also known as F 11782) is an epipodophyllotoxin derivative patented by Pierre Fabre Medicament as an antitumor agent. Tafluposide acts as a catalytic inhibitor of topoisomerases I and II, that capable of completely inhibiting the DNA-binding activity of topoisomerase. In preclinical models single or multiple i.p. doses of Tafluposide proves highly active against the s.c. grafted B16 melanoma, significantly increasing survival and inhibiting tumor growth. Tafluposide inhibits the number of pulmonary metastatic foci of the melanoma by 99%. In human tumor xenograft studies, multiple i.p. doses of Tafluposide results in major inhibitory activity against breast) tumors, as well as causing definite tumor regression. Significant activity was also recorded Tafluposide against the refractory lung xenografts.

Taloximine, an analeptic drug that was developed as a respiratory stimulant with bronchodilator properties. Information about the current use of this drug is not available.

Tamethicillin is a basic ester pro-drug of methicillin (MET) which is converted in the body by non-specific esterases to MET. Tamethicillin was used as an antibacterial agent in the veterinary as a useful alternative for the treatment of mastitis in livestock, especially in mastitis due to beta-lactamase-producing Staphylococcus.

Nemorubicin, a doxorubicin derivative, is a DNA-intercalator, topoisomerase and RNA synthesis inhibitor that was undergoing development with Nerviano Medical Sciences (Nerviano MS; formerly Pharmacia Italia) for the treatment of solid tumours, specifically, the loco-regional treatment of primary liver tumours (hepatocellular carcinoma). The drug is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives. It works primarily through topoisomerase I inhibition. Of note, Nemorubicin is active in cells with upregulation of the nucleotide excision repair (NER) pathway, where current therapies fail. Nemorubicin is biotransformed in the liver into cytotoxic metabolites that may further contribute to render this drug highly active against primary liver tumors or liver metastases. Clinical trials were conducted in Europe, US and China with Nemorubicin given at different dose-schedules and by different routes of administration: as single agent by systemic IV route, oral route and by intra-hepatic artery (IHA) infusion alone or in combination with cisplatin.

Oxibetaine was developed as a lipotropic agent. Information about the current use of this compound is not available.